TERC rs35073794 is associated with about 4.4-fold decreased odds of MS occurrence in men according to the codominant, dominant, and overdominant models (OR: 0.228, (95% CI: 0.124–0.417), p < 0.001; OR: 0.233 (95% CI: 0.128–0.427), p < 0.001; OR: 0.224 (95% CI: 0.122–0.410), p < 0.001, respectively). Here, TERC is linked to myeloid sarcoma.